

RECEIVED
CENTRAL FAX CENTER

FEB 06 2004

OFFICIAL

Bereskin & Parr
INTELLECTUAL PROPERTY LAWScotia Plaza, 40 King Street West, 40th Floor
Toronto, Ontario, Canada M5H 3Y2
t: 416 364 7311 f: 416 361 1398**AFTER FINAL****TELEFAX TRANSMITTAL**

TO: United States Patent and Trademark Office

ATTN: Samuel Wei Liu – Examiner, Art Unit 1653

FAX NO.: 703-872-9306 Tel: 571-272-0949

RE: Serial No. 09/551,151 Our file: 10447-11


FROM: Micheline Gravelle, Registration No. 40,261

DATE: February 4, 2004 PAGES: 8
(Including cover sheet)

If transmission is interrupted or of poor quality, please notify us immediately by calling Jenny Lo at (416) 364-7311, ext. 6277.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the attached Response and Terminal Disclaimer are being facsimile transmitted to the U.S. Patent & Trademark Office on the date shown below.



Micheline Gravelle
Registration No. 40,261

February 4, 2004
Date

CONFIDENTIAL

This communication may contain information that is privileged or confidential and is intended only for the use of the individual to whom it is addressed. Any other distribution, copying or disclosure is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.

Appl. No. 09/551,151
Amdt. Dated February 4, 2004
Reply to Office action of November 4, 2003

OFFICIAL

Appl. No : 09/551,151
Applicant : Thor Borgford
Filed : April 14, 2000
Title : Ricin-Like Toxin Variants For Treatment of Cancer,
Viral or Parasitic Infections
TC./A.U. : 1653
Examiner : Samuel W. Liu

Confirmation No.: 1104

**RECEIVED
CENTRAL FAX CENTER**

FEB 06 2004

Docket No. : 10447-11
Customer No. : 001059

AFTER FINAL**By Facsimile**

Honorable Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT

Sir:

The present letter is filed in response to the office action dated November 4, 2003.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.